儿童急性淋巴细胞白血病融合基因与预后的关系

Advances in the application of mesenchymal stem cells in sepsis

摘要:

脓毒症是危急重症医学常年面临的重要问题，是危及危重病患者生命的主要原因之一，且患病率不断增加，但目前尚无有效的治疗方法。近年来间充质干细胞（MSCs）因其免疫调节、抗菌、调节器官衰竭、抗凋亡、抗炎症小体等特性应用于治疗脓毒症的临床前研究，其特性与脓毒症的发病机制有较多联系，该文阐述MSCs治疗脓毒症的相关知识以及目前在体内外治疗脓毒症的相关研究，以探讨MSCs治疗脓毒症新思路和未来的努力方向。

Abstract:

Sepsis is an important problem faced by critically ill patients in critical care for a long time. It is one of the main causes threatening life of critically ill patients, and the prevalence rate is increasing. However, there is no effective treatment. In recent years, mesenchymal stem cells (MSCs) have been used in preclinical studies for the treatment of sepsis due to their properties, including immunomodulatory, antibacterial, regulating organ failure, anti-apoptosis, and anti-inflammasome which are more related to the pathogenesis of sepsis. This article describes the relevant knowledge of MSCs in the treatment of sepsis and the current research on the treatment of sepsis in vitro and in vivo in order to explore new ideas and future efforts of MSCs in the treatment of sepsis.